BridgeBio price target raised to $95 from $60 at TD Cowen

TD Cowen raised the firm’s price target on BridgeBio (BBIO) to $95 from $60 and keeps a Buy rating on the shares. The firm said the 51% quarter-over-quarter Attruby sales growth beat expectations and was driven by treatment naive patients and accelerating new patient prescriptions. BridgeBio remains focused on the Attruby launch and the late-stage pipeline and is two-for-two so far with positive LGMD and ADH1 readouts set to be released.